|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the Research To Practice scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — Dr Carey had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Goss — Advisory Committee: GlaxoSmithKline, Novartis Pharmaceuticals Corporation; Paid Speaker: Pfizer Inc, Wyeth. Dr Hayes — Paid Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Pfizer Inc. Dr Lipton — Consulting Agreements: Amgen Inc, Incyte Corporation, Merck and Company Inc, Monogram Biosciences, Novartis Pharmaceuticals Corporation; Expert Testimony: Novartis Pharmaceuticals Corporation; Paid Research: Monogram Biosciences, Novartis Pharmaceuticals Corporation; Speakers Bureau: Amgen Inc, Novartis Pharmaceuticals Corporation. Dr Seidman — Consulting Agreement: Wyeth; Speakers Bureau: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Genomic Health Inc. Dr Sledge — Advisory Committee: Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation; Consulting Agreement: Genentech BioOncology; Paid Research: Eli Lilly and Company, Sanofi-Aventis.
MODERATOR — Neil Love: Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, OSI Oncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Synta Pharmaceuticals Corp and Wyeth.
RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
 |
 |
